HD-OPM Archive
Topics › Statins

Statins associated with lower advanced and fatal prostate cancer and longer survival

Louis Nervegna · Aug 26, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
StatinsCancer
AI summary & key facts

Louis cites a 2022 review of the epidemiology of statins and prostate cancer. Registry and cohort studies find statin use linked to lower advanced and fatal prostate cancer risk and longer survival in men already diagnosed. These are observational associations.

Statins & Prostate Cancer
Statin use is associated with lower risk of both advanced and fatal prostate cancer, and with longer survival in men who already have prostate cancer.

Review article:

Paper · Prostate Cancer Prostatic Dis · 2022Statins and prostate cancer—hype or hope? The epidemiological perspectiveBackground Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Statin use has also been associated with longer survival among men already diagnosed with prostate cancer. Mechanisms responsible for purported anti-cancer effects of statins are not well understood but may offer…nature.com

Quoted:

Background

Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Statin use has also been associated with longer survival among men already diagnosed with prostate cancer. Mechanisms responsible for purported anti-cancer effects of statins are not well understood but may offer insight into prostate cancer biology.

Results

Data from prospective observational studies generally reported a lower risk of fatal prostate cancer among statin users. There is some evidence for serum cholesterol-lowering as an indirect mechanism linking statins with advanced and fatal prostate cancer. Window-of-opportunity clinical trials show measurable levels of statins in prostate tissue highlighting potential for direct effects, whilst observational data suggest possible statin-driven modulation of prostate microenvironment inflammation. Additionally, emerging data from registry studies support a potential role for statins within the context of androgen deprivation therapy and anti-androgen treatment.

Conclusion

Prospective and registry-based studies support a lower risk of advanced and fatal prostate cancer in statin users relative to non-users, as well as better outcomes among prostate cancer patients. The few randomised-controlled trials conducted so far have short follow-up, lack identified molecular subgroups, and do not provide additional support for the observational results. Consequently, additional evidence is required to determine which men may experience greatest benefit in terms of prostate cancer-specific outcomes and how statin effects may vary according to molecular tumour characteristics.

Research cited

#cancer#prostatecancer#statins#cholesterol#prospectivecohortstudies#inflammation
← newer: Six converging evidence lines favor plant protein over red aolder: Isoleucine and valine fuel prostate cancer by boosting tumor →